Home Cart 0 Sign in  

[ CAS No. 218600-53-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 218600-53-4
Chemical Structure| 218600-53-4
Structure of 218600-53-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 218600-53-4 ]

Related Doc. of [ 218600-53-4 ]

Alternatived Products of [ 218600-53-4 ]

Product Details of [ 218600-53-4 ]

CAS No. :218600-53-4 MDL No. :MFCD11983137
Formula : C32H43NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :WPTTVJLTNAWYAO-KPOXMGGZSA-N
M.W : 505.69 Pubchem ID :400769
Synonyms :
RTA 402;NSC 713200;CDDO-Me;TP-155;CDDO Methyl ester

Calculated chemistry of [ 218600-53-4 ]

Physicochemical Properties

Num. heavy atoms : 37
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 2
Num. H-bond acceptors : 5.0
Num. H-bond donors : 0.0
Molar Refractivity : 144.29
TPSA : 84.23 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -4.61 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.83
Log Po/w (XLOGP3) : 6.72
Log Po/w (WLOGP) : 6.38
Log Po/w (MLOGP) : 4.16
Log Po/w (SILICOS-IT) : 6.33
Consensus Log Po/w : 5.48

Druglikeness

Lipinski : 2.0
Ghose : None
Veber : 0.0
Egan : 1.0
Muegge : 1.0
Bioavailability Score : 0.17

Water Solubility

Log S (ESOL) : -7.08
Solubility : 0.0000424 mg/ml ; 0.0000000838 mol/l
Class : Poorly soluble
Log S (Ali) : -8.29
Solubility : 0.00000257 mg/ml ; 0.0000000051 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -7.19
Solubility : 0.0000326 mg/ml ; 0.0000000644 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 5.97

Safety of [ 218600-53-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 218600-53-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 218600-53-4 ]
  • Downstream synthetic route of [ 218600-53-4 ]

[ 218600-53-4 ] Synthesis Path-Upstream   1~15

  • 1
  • [ 1428550-98-4 ]
  • [ 218600-53-4 ]
YieldReaction ConditionsOperation in experiment
83.6% With potassium iodide In N,N-dimethyl-formamide at 120℃; for 30 h; 5.58 g of compound V (10 mmol) were dissolved in 80 ml of anhydrous DMF, 1.1648 g of cuprous cyanide (13 mmol) and0.332 g of potassium iodide (2 mmol) was added, and a balloon was added to prevent the water in the air from entering the reaction system and reacting at 120 ° C for 30 hours. reactionAfter the reaction was cooled to room temperature, the reaction solution was poured into 200ml of water to quench, add 500ml of ethyl acetate, stir, filterThe insolubles were removed and the organic layer was washed with saturated sodium bicarbonate (200 ml x 2) and saturated sodium chloride (200 ml), respectively,Drying, suction filtration, rotary drying and column chromatography (PE / EA = 5: 1) gave 4.22 g of yellow powder with a yield of 83.6percent.
73% With potassium iodide In N,N-dimethyl-formamide at 120℃; As shown in Scheme 4, the natural triterpenoid oleanolic acid (1) was used as the starting material in the synthesis of CDDO-Me. The improved method commences with methylation of the carboxylic acid of oleanolic acid (1) to afford methyl ester 2 in quantitative yield. With ester 2, activation of the A-ring is fulfilled by 2-iodoxybenzoic acid-mediated two-fold oxidation to give enone 3. Epoxidation with meta-chloroperoxybenzoic acid, followed by direct C-ring enolization and A-ring enone bromination with bromine and hydrobromic acid, affords key intermediate 4. With bromide 4 in hand, a cross-coupling reaction with copper cyanide provides CDDO-Me (5) in only five steps (four operations) from oleanolic acid (Scheme 4). This is an improvement over conventional methods, which require 10 steps. Moreover, intermediate 4 was prepared in high yield and few overall steps, thereby providing a base compound for development of additional analogs and derivatives.
73% With potassium iodide In N,N-dimethyl-formamide at 120℃; As a specific example of using this synthetic method in the synthesis of triterpenoids, CDDO-Me was synthesized from oleanolic acid. As shown in Scheme 2, the natural triterpenoid oleanolic acid (1) was used as the starting material in the synthesis of CDDO-Me. The method commences with methylation of the carboxylic acid of oleanolic acid (1) to afford methyl ester 2 in quantitative yield. With ester 2, activation of the A-ring is fulfilled by 2-iodoxybenzoic acid-mediated two-fold oxidation to give enone 3. Epoxidation with meta-chloroperoxybenzoic acid, followed by direct C-ring enolization and A-ring enone bromination with bromine and hydrobromic acid, affords key intermediate 4. With bromide 4 in hand, a cross-coupling reaction with copper cyanide provides CDDO-Me (5) (Scheme 2). Intermediate 4 was prepared in high yield and few overall steps, thereby providing a base compound for development of the analogs and derivatives described herein.
Reference: [1] Patent: CN106632576, 2017, A, . Location in patent: Paragraph 0058; 0059; 0060; 0061
[2] Patent: US2013/303797, 2013, A1, . Location in patent: Paragraph 0106
[3] Patent: US2013/303607, 2013, A1, . Location in patent: Paragraph 0103
[4] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
  • 2
  • [ 1198076-59-3 ]
  • [ 218600-53-4 ]
Reference: [1] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
  • 3
  • [ 305818-40-0 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
  • 4
  • [ 508-02-1 ]
  • [ 218600-53-4 ]
Reference: [1] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[2] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[3] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[4] Patent: US2013/303797, 2013, A1,
[5] Patent: US2013/303607, 2013, A1,
[6] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
[7] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
[8] Patent: CN106632576, 2017, A,
  • 5
  • [ 69660-90-8 ]
  • [ 218600-53-4 ]
Reference: [1] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[2] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[3] Patent: US2013/303797, 2013, A1,
[4] Patent: US2013/303607, 2013, A1,
[5] Patent: CN106632576, 2017, A,
  • 6
  • [ 1724-17-0 ]
  • [ 218600-53-4 ]
Reference: [1] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[2] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[3] Organic Letters, 2013, vol. 15, # 7, p. 1622 - 1625
[4] Patent: US2013/303797, 2013, A1,
[5] Patent: US2013/303607, 2013, A1,
[6] Patent: CN106632576, 2017, A,
  • 7
  • [ 65023-20-3 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
[2] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 19, p. 2711 - 2714
[3] Patent: US9278913, 2016, B2,
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
  • 8
  • [ 218600-50-1 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
[2] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 19, p. 2711 - 2714
[3] Patent: US9278913, 2016, B2,
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
  • 9
  • [ 65023-19-0 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
[2] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 19, p. 2711 - 2714
[3] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
  • 10
  • [ 218600-52-3 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
[2] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 19, p. 2711 - 2714
  • 11
  • [ 305818-39-7 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 22, p. 4233 - 4246
  • 12
  • [ 218600-51-2 ]
  • [ 218600-53-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 19, p. 2711 - 2714
[2] Patent: US9278913, 2016, B2,
  • 13
  • [ 25493-69-0 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
  • 14
  • [ 4339-72-4 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
  • 15
  • [ 25493-94-1 ]
  • [ 218600-53-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2396 - 2409
Same Skeleton Products
Historical Records